Lauren P Wallner1, Jin-Wen Y Hsu2, Ronald K Loo3, Darryl E Palmer-Toy4, Joanne E Schottinger5, Steven J Jacobsen2. 1. Department of Medicine and Comprehensive Cancer Center, Institute for Healthcare Policy and Innovation, University of Michigan; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA. Electronic address: lwallner@med.umich.edu. 2. Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA. 3. Department of Urology, Southern California Permanente Medical Group, Pasadena, CA. 4. Regional Reference Laboratories, Kaiser Permanente Southern California, Los Angeles, CA. 5. Department of Quality and Clinical Analysis, Kaiser Permanente Southern California, Pasadena, CA.
Abstract
OBJECTIVE: To determine whether the rates of prostate-specific antigen (PSA) screening, related biopsies and subsequent prostate cancer utilization decreased between 2000 and 2012 in a large, managed care organization. METHODS: Male members of Kaiser Permanente Southern California who were aged ≥40 years and had no history of prostate cancer (N = 15,326) were passively followed through electronic health plan files from January 1, 2000, through December 31, 2012 (N = 1,539,469). The rates of PSA testing, elevated PSA tests, prostate biopsies, prostate cancer treatment (surgery and radiation), and urology visits were calculated per year among eligible men and stratified by age group. RESULTS: A 59% decrease in PSA screening occurred among men aged ≥75 years beginning in 2008, followed by 49% in ages 65-74, 20% in ages 50-64, and 33% in ages 40-49 years in 2009. However, the number of elevated PSA tests remained largely unchanged in all groups except in men aged ≥75 years (45% decrease). Prostate biopsy rates and urology visits remained consistent among elderly men. CONCLUSION: Among men in this managed care setting, although there was a sharp decline in PSA testing among men aged ≥75 years after 2008, prostate biopsy rates remained constant, and subsequent prostate cancer treatment remained highest among men in this age group. These results suggest that the guidelines recommending against PSA and the subsequent provider-targeted interventions implemented in this system resulted in decreased screening across age groups and potentially led to more discriminant screening among those aged ≥75 years.
OBJECTIVE: To determine whether the rates of prostate-specific antigen (PSA) screening, related biopsies and subsequent prostate cancer utilization decreased between 2000 and 2012 in a large, managed care organization. METHODS: Male members of Kaiser Permanente Southern California who were aged ≥40 years and had no history of prostate cancer (N = 15,326) were passively followed through electronic health plan files from January 1, 2000, through December 31, 2012 (N = 1,539,469). The rates of PSA testing, elevated PSA tests, prostate biopsies, prostate cancer treatment (surgery and radiation), and urology visits were calculated per year among eligible men and stratified by age group. RESULTS: A 59% decrease in PSA screening occurred among men aged ≥75 years beginning in 2008, followed by 49% in ages 65-74, 20% in ages 50-64, and 33% in ages 40-49 years in 2009. However, the number of elevated PSA tests remained largely unchanged in all groups except in men aged ≥75 years (45% decrease). Prostate biopsy rates and urology visits remained consistent among elderly men. CONCLUSION: Among men in this managed care setting, although there was a sharp decline in PSA testing among men aged ≥75 years after 2008, prostate biopsy rates remained constant, and subsequent prostate cancer treatment remained highest among men in this age group. These results suggest that the guidelines recommending against PSA and the subsequent provider-targeted interventions implemented in this system resulted in decreased screening across age groups and potentially led to more discriminant screening among those aged ≥75 years.
Authors: Anita D Misra-Hebert; Bo Hu; Eric A Klein; Andrew Stephenson; Glen B Taksler; Michael W Kattan; Michael B Rothberg Journal: BJU Int Date: 2017-02-26 Impact factor: 5.588
Authors: Vincent Beck; Boris Schlenker; Annika Herlemann; Maria Apfelbeck; Alexander Buchner; Christian Gratzke; Christian G Stief; Stefan Tritschler Journal: World J Urol Date: 2018-09-17 Impact factor: 4.226
Authors: Glen Gejerman; Patrick Ciccone; Martin Goldstein; Vincent Lanteri; Burton Schlecker; John Sanzone; Michael Esposito; Sergey Rome; Michael Ciccone; Eric Margolis; Robert Simon; Yijun Guo; Sri-Ram Pentakota; Hossein Sadeghi-Nejad Journal: Investig Clin Urol Date: 2017-11-02